A citation-based method for searching scientific literature

Entrectinib in ROS1 fusion-positive non-small-cell lung cancer: integrated analysis of three phase 1-2 trials.
Alexander Drilon, Salvatore Siena, Rafal Dziadziuszko, Fabrice Barlesi, Matthew G Krebs, Alice T Shaw, Filippo de Braud, Christian Rolfo, Myung-Ju Ahn, Jürgen Wolf, Takashi Seto, Byoung Chul Cho, Manish R Patel, Chao-Hua Chiu, Thomas John, Koichi Goto, Christos S Karapetis, Hendrick-Tobias Arkenau, Sang-We Kim, Yuichiro Ohe, Yu-Chung Li, Young K Chae, Christine H Chung, Gregory A Otterson, Haruyasu Murakami, Chia-Chi Lin, Daniel S W Tan, Hans Prenen, Todd Riehl, Edna Chow-Maneval, Brian Simmons, Na Cui, Ann Johnson, Susan Eng, Timothy R Wilson, Robert C Doebele. Lancet Oncol 2020
Times Cited: 153



Tepotinib in Non-Small-Cell Lung Cancer with MET Exon 14 Skipping Mutations.
Paul K Paik, Enriqueta Felip, Remi Veillon, Hiroshi Sakai, Alexis B Cortot, Marina C Garassino, Julien Mazieres, Santiago Viteri, Helene Senellart, Jan Van Meerbeeck, Jo Raskin, Niels Reinmuth, Pierfranco Conte, Dariusz Kowalski, Byoung Chul Cho, Jyoti D Patel, Leora Horn, Frank Griesinger, Ji-Youn Han, Young-Chul Kim, Gee-Chen Chang, Chen-Liang Tsai, James C-H Yang, Yuh-Min Chen, Egbert F Smit, Anthonie J van der Wekken, Terufumi Kato, Dilafruz Juraeva, Christopher Stroh, Rolf Bruns, Josef Straub, Andreas Johne, Jürgen Scheele, John V Heymach, Xiuning Le. N Engl J Med 2020
Times Cited: 192




List of shared articles



Times cited

Rare driver alterations in nonsmall cell lung cancer: novel targeted drugs.
Diego Kauffmann-Guerrero, Amanda Tufman. Curr Opin Oncol 2022
1

Performance of Japanese patients in registrational studies.
Yasushi Goto, Sayaka Arakawa, Masayuki Shirasawa, Ryoko Higashiyama, Keisuke Baba, Ken Masuda, Yuki Shinno, Yuji Matsumoto, Yusuke Okuma, Tatsuya Yoshida,[...]. Jpn J Clin Oncol 2022
0

Targeted Therapies for Lung Cancer Patients With Oncogenic Driver Molecular Alterations.
Aaron C Tan, Daniel S W Tan. J Clin Oncol 2022
9

Complications following novel therapies for non-small cell lung cancer.
Marcus Skribek, Konstantinos Rounis, Georgios Tsakonas, Simon Ekman. J Intern Med 2022
0

Efficacy of targeted therapies for oncogene-driven lung cancer in early single-arm versus late phase randomized clinical trials: A comparative analysis.
Aaron C Tan, Sze Huey Tan, Siqin Zhou, Solange Peters, Giuseppe Curigliano, Daniel S W Tan. Cancer Treat Rev 2022
0

A Need for More Molecular Profiling in Brain Metastases.
Erica Shen, Amanda E D Van Swearingen, Meghan J Price, Ketan Bulsara, Roeland G W Verhaak, César Baëta, Brice D Painter, Zachary J Reitman, April K S Salama, Jeffrey M Clarke,[...]. Front Oncol 2022
0

Targeted therapy in lung cancer: Are we closing the gap in years of life lost?
David J Benjamin, Alyson Haslam, Jenny Gill, Vinay Prasad. Cancer Med 2022
0

Novel targeted therapies for advanced non-small lung cancer.
Omar Abughanimeh, Anahat Kaur, Badi El Osta, Apar Kishor Ganti. Semin Oncol 2022
0

Molecular lung cancer: How targeted therapies and personalized medicine are re-defining cancer care.
Zachary L Quinn, Julie A Barta, Jennifer M Johnson. Am J Med Sci 2022
0

Biomarker guided treatment in oncogene-driven advanced non-small cell lung cancer in older adults: A Young International Society of Geriatric Oncology Report.
Konstantinos Christofyllakis, Ana Raquel Monteiro, Onur Cetin, Igor Age Kos, Alastair Greystoke, Andrea Luciani. J Geriatr Oncol 2022
0

Non-Small Cell Lung Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology.
David S Ettinger, Douglas E Wood, Dara L Aisner, Wallace Akerley, Jessica R Bauman, Ankit Bharat, Debora S Bruno, Joe Y Chang, Lucian R Chirieac, Thomas A D'Amico,[...]. J Natl Compr Canc Netw 2022
1

Targeting Infrequent Driver Alterations in Non-Small Cell Lung Cancer.
Marie-Julie Nokin, Chiara Ambrogio, Ernest Nadal, David Santamaria. Trends Cancer 2021
4

Breakthrough in targeted therapy for non-small cell lung cancer.
Zhencong Ye, Yongmei Huang, Jianhao Ke, Xiao Zhu, Shuilong Leng, Hui Luo. Biomed Pharmacother 2021
19

Genomic profiling in non-small-cell lung cancer in young patients. A systematic review.
D Viñal, D Martínez, O Higuera, J de Castro. ESMO Open 2021
6

Therapy for Stage IV Non-Small-Cell Lung Cancer With Driver Alterations: ASCO and OH (CCO) Joint Guideline Update.
Nasser H Hanna, Andrew G Robinson, Sarah Temin, Sherman Baker, Julie R Brahmer, Peter M Ellis, Laurie E Gaspar, Rami Y Haddad, Paul J Hesketh, Dharamvir Jain,[...]. J Clin Oncol 2021
64

Targeted Therapy in Advanced and Metastatic Non-Small Cell Lung Cancer. An Update on Treatment of the Most Important Actionable Oncogenic Driver Alterations.
David König, Spasenija Savic Prince, Sacha I Rothschild. Cancers (Basel) 2021
23

The evolving paradigm of precision medicine in lung cancer.
Francesco Passiglia, Giorgio V Scagliotti. Curr Opin Pulm Med 2021
0

Oncogenic driver mutations in non-small cell lung cancer: Past, present and future.
Mathieu Chevallier, Maxime Borgeaud, Alfredo Addeo, Alex Friedlaender. World J Clin Oncol 2021
10

[NSCLC and new oncogenic mutations: Diagnosis and perspectives].
C Basse, A Swalduz, A Mc Leer, D Moro-Sibilot, J Remon, N Girard. Rev Mal Respir 2021
0

Selecting the optimal immunotherapy regimen in driver-negative metastatic NSCLC.
Michael J Grant, Roy S Herbst, Sarah B Goldberg. Nat Rev Clin Oncol 2021
18

Precision Medicine in Oncology: A Review of Multi-Tumor Actionable Molecular Targets with an Emphasis on Non-Small Cell Lung Cancer.
Matthew K Stein, Oluchukwu Oluoha, Kruti Patel, Ari VanderWalde. J Pers Med 2021
4

Anti-PD1/PD-L1 Immunotherapy for Non-Small Cell Lung Cancer with Actionable Oncogenic Driver Mutations.
Edouard Dantoing, Nicolas Piton, Mathieu Salaün, Luc Thiberville, Florian Guisier. Int J Mol Sci 2021
7

Targeted therapy in advanced non-small cell lung cancer: current advances and future trends.
Umair Majeed, Rami Manochakian, Yujie Zhao, Yanyan Lou. J Hematol Oncol 2021
13

Lung cancer.
Alesha A Thai, Benjamin J Solomon, Lecia V Sequist, Justin F Gainor, Rebecca S Heist. Lancet 2021
81

Update on molecular pathology and role of liquid biopsy in nonsmall cell lung cancer.
Pamela Abdayem, David Planchard. Eur Respir Rev 2021
0

The rapidly evolving landscape of novel targeted therapies in advanced non-small cell lung cancer.
Barbara Melosky, Paul Wheatley-Price, Rosalyn A Juergens, Adrian Sacher, Natasha B Leighl, Ming-Sound Tsao, Parneet Cheema, Stephanie Snow, Geoffrey Liu, Paul B Card,[...]. Lung Cancer 2021
12

Toward personalized treatment approaches for non-small-cell lung cancer.
Meina Wang, Roy S Herbst, Chris Boshoff. Nat Med 2021
30

The Value of Population Screening in Advancing Personalized Medicine in the Field of Lung Cancer.
Alice Mogenet, Laurent Greillier, Pascale Tomasini. Pharmgenomics Pers Med 2021
1

How clinically useful is comprehensive genomic profiling for patients with non-small cell lung cancer? A systematic review.
Gabriel Fernando Torres, Carlos Eduardo Bonilla, Giancarlo Buitrago, Oscar Arrieta, Umberto Malapelle, Christian Rolfo, Andrés F Cardona. Crit Rev Oncol Hematol 2021
2

Response to Immune Checkpoint Inhibition as Monotherapy or in Combination With Chemotherapy in Metastatic ROS1-Rearranged Lung Cancers.
Noura J Choudhury, Jaime L Schneider, Tejas Patil, Viola W Zhu, Debra A Goldman, Soo-Ryum Yang, Christina J Falcon, Andrew Do, Yunan Nie, Andrew J Plodkowski,[...]. JTO Clin Res Rep 2021
3


Longstocking, LLC. © 2021
Home | About Us | FAQs | Terms & Privacy